Our proprietary PETization platform enables the rapid translation of therapeutic monoclonal antibodies (mAbs) between species.
Our mAbs are uniquely designed to be accepted by a patient's immune system as "native," a property we refer to as "100% species-specificity."
Our most advanced therapies in development are focused on treatments within four general areas: chronic pain, chronic inflammation, allergy, and immuno-oncology (cancer).
We believe biologic therapies as a class offer significant advantages over current treatments in these areas, including: safety, longer duration of action (and therefore less frequent dosing), and injectability.
Our team of scientists and veterinarians are working to investigate further opportunities for new biologic therapies.
27–30 July 2016
Veterinary Pain Short Course, San Diego, CA, U.S.
17–19 August 2016
International Veterinary Immunology Symposium, Gold Coast, Australia
8–10 September 2016
European Society of Veterinary Orthopaedics and Traumatology, London, U.K.
26-30 September 2016
World Congress on Pain, Yokohama, Japan
6-8 November 2016
Credit Suisse Healthcare Conference, Scottsdale, AZ, U.S.
9–12 January 2017
J.P.Morgan Annual Healthcare Conference, San Francisco, CA, U.S.
22-23 February 2017
European Animal Health Investment Forum, London, UK.
3-6 March 2017
Cowen and Company Annual Healthcare Conference, Boston, MA, U.S.
Unit 5, Sragh Technology Park
Rahan Road, Tullamore
Co. Offaly, R35 FR98
P: + 353 5793 24522
Level 8, 31 Queen Street
P: +61 (3) 9610 4400
275 Post Street
San Francisco, CA 94108